[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-pain":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,59,0,25,[9,46,72,101,129,141,165,191,215,242,272,294,332,353,380,409,444,469,479,501,526,545,585,601,629],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100054326","dose-response-effects-of-a-brief-audio-guided-mindfulness-intervention-for-acute-pain-100054326",false,"NCT07562412","Dose-Response Effects of a Brief Audio-Guided Mindfulness Intervention for Acute Pain","Dose-Response Effects of a Brief Audio-Guided Mindfulness Intervention for Acute Pain While Awaiting Orthopedic Care","Inclusion Criteria:\n\n* Receiving treatment at Tallahassee Orthopedic Center\n* Understanding English instructions fluently\n* Being 18 years of age or older\n\nExclusion Criteria:\n\n* Unable to consent because of physical or mental incapacity.","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","This project is a single-site, three-arm, randomized controlled trial investigating whether different length audio-recorded mindfulness practices differentially decrease pain among patients in a waiting room awaiting orthopedic care.",[27,28,29,30,31,32],"Pain","Pain Management","Mindfulness","Orthopedic","Acute Pain","Chronic Pain","RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-04-29",{"date":41,"type":21},"2027-04-30",{"name":43,"class":44},"Florida State University","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":45},"100053978","human-experimental-models-of-pain-hemp-100053978","NCT07549490","Human Experimental Models of Pain (HEMP)","A Pilot Study for Developing a Comprehensive Signal Detection Approach for the Mechanisms of Action and Analgesic Efficacy of Two Analgesics Using Human Experimental Models of Pain (HEMP)","* INCLUSION CRITERIA:\n\nFor an individual to be eligible to participate in this study, they must meet all of the following criteria:\n\n* Voluntarily consent to participate and provide written informed consent prior to the start of any study-specific procedures.\n* Read and speak English fluently.\n* State willingness to comply with all study procedures and availability for the duration of the study.\n* Are not pregnant or breastfeeding.\n* Are 18 or older years of age at screening.\n* Have a skin type score between 2 and 5 (inclusive) on the Fitzpatrick Scale.\n* Must correctly identify at least nine out of 12 temperatures (32 degrees Celsius, 38 degrees Celsius, 44 degrees Celsius, and 50 degrees Celsius, each presented three times) during the sensory discrimination test at screening.\n* Provide a verbal pain rating between 4 and 9 (inclusive) during the intradermal capsaicin challenge at screening. The study team will verify tolerability, and participants will continue only after it has been confirmed.\n* During the cold pressor test at screening, provide a verbal pain rating between 4 and 9 (inclusive) and keep one hand completely immersed in ice-cold water (1-4 degrees Celsius) between 1 and 4 minutes (inclusive). The study team will verify tolerability, and participants will continue only after it has been confirmed.\n* Are able to learn and perform all quantitative sensory testing QST procedures (see the separate QST manual).\n* Have the ability to take oral medication and be willing to adhere to the study intervention regimen.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Have a history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the participant or the validity of the study results.\n* Have alcohol or drug dependence (excluding nicotine and caffeine) within the past 2 years, as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM IV-TR) and\u002For participants who have ever been in a substance or alcohol rehabilitation program to treat their substance dependence are currently seeking such treatment.\n* Have a clinically significant abnormal finding on the physical exam, medical history, or clinical laboratory results at screening.\n* Have a history of psychotic reactions, a non-psychotic emotional disorder, or another mental illness that, in the opinion of the investigator, may affect the ability of the participant to participate in the study.\n* Have recent history of suicidal ideation or suicidal behavior within the past 6 months, as assessed by the Columbia- Suicide Severity Rating Scale (C-SSRS) at screening (baseline version) or at check-in ( Since Last Visit version).\n* Have a history of allergy or hypersensitivity to pregabalin or other gabapentinoids, naproxen or other NSAIDs, or another ingredient in the study drugs, or anything else that, in the opinion of the Investigator, could put the participant at risk.\n* Have participated in another clinical trial (randomized participants only) within 30 days prior to the first dose of study medication.\n* Use any prescription medication, except hormonal contraceptive or hormonal replacement therapy, from 14 days prior to the first dose of study medication until study participation has ended without evaluation and approval by the Investigator.\n* Donate blood or plasma within 30 days prior to the first dose of study medication until the end of study participation. It is recommended that participants not donate blood or plasma until at least 30 days after their study participation has ended.\n* Female participants who are currently pregnant or breastfeeding, or who are planning to become pregnant during the study or within 30 days after the last study drug administration.\n* Show a positive urine alcohol test at screening.\n* Have smoked or used tobacco- or nicotine-containing products within 30 days prior to the first dose of study treatment until the end of the study.\n* Have an allergy to capsaicin or another capsaicinoid.\n* Have a tattoo, excessive scarring or discoloration, keloid formation, or, at the Investigator s discretion, otherwise unhealthy skin (e.g., eczema, psoriasis, burn, and cut) at a QST site.\n* Have a significant history of nerve injury or damage at a QST site, at the Investigator s discretion.\n* Participants who report any stimulus as intolerable at any point during the screening procedures will be excluded from participation.",true,"100 Years",{"count":7,"type":21},[24],"This pilot study will test an innovative way to establish how pain medicines provide analgesia in healthy adults. The study uses a group of short, controlled pain tests to look at different types of pain responses in the body. The main goal is to find out if this testing approach can show the pain-relieving effects of 2 medicines, pregabalin and naproxen versus placebo, and show how they provide relief of different types of pain.\n\nThe study hypothesis is that this pain testing approach administered as a battery would be able to tell the difference between a medicine that works mainly in the brain and spinal cord (pregabalin) and a medicine that works mainly on inflammation in body tissues (naproxen).\n\nUp to 25 healthy adults will take part. Each participant will receive all 3 study treatments, pregabalin, naproxen, and placebo, administered in random order during separate study periods. The order will be assigned by chance. Neither the participant nor the study team will know which treatment is given at each visit.\n\nThe study includes several experimental pain tests. These include:\n\na heat and capsaicin skin test that causes short-term skin sensitivity,\n\na UVB light test that causes a temporary sunburn-like sensitivity, and\n\na cold pressor test, in which a hand is placed in very cold water for a short time.\n\nParticipants will also have sensory testing to measure how they feel touch, pressure, pinprick, warmth, heat, and cold. Blood samples will be collected to measure study drug levels. Urine samples, vital signs, and other safety checks will also be done.\n\nEach treatment visit includes testing before and for several hours after taking the study drug. There will be a washout period of at least 48 hours between treatments. Total participation may last up to about 10 weeks.\n\nThis study is not expected to provide direct medical benefit to participants. The information learned may help researchers improve early testing of future pain treatments....",[31],[60,61,62],"Human Experimental Models of Pain","HCM (Heat\u002FCapsaicin Pain Model)","Pain Mechanisms","NOT_YET_RECRUITING",{"date":36,"type":37},{"date":66,"type":21},"2026-07-16",{"date":68,"type":21},"2030-12-31",{"name":70,"class":71},"National Center for Complementary and Integrative Health (NCCIH)","NIH",{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":17,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100053850","rebooting-infant-pain-care-using-machine-learning-and-skin-to-skin-contact-to-exponentially-improve-neonatal-intensive-care-unit-practice-100053850","NCT05579496","Rebooting Infant Pain Care: Using Machine Learning and Skin-to-Skin Contact to Exponentially Improve Neonatal Intensive Care Unit Practice","BabyAIBabyCalm","QUALITATIVE INTERVIEWS\n\nInclusion Criteria:\n\n* Parents of a child currently in the NICU or\n* Health professionals currently working in the NICU.\n\nExclusion Criteria:\n\n\\*Participants who cannot communicate fluently in English\n\nQUANTITITATIVE DATA CAPTURE (video, eeg, ecg, RR, SPo2)\n\nInclusion Criteria:\n\n* Infants born between 25 0\u002F7 weeks 32 6\u002F7 weeks gestational age\n* Infants who are within 8 weeks postnatal age\n* Infants who are undergoing a routine heel lance\n\nExclusion Criteria:\n\n* Infants with congenital malformations\n* Infants receiving analgesics or sedatives at the time of study (aside from sucrose)\n* Infants with history of perinatal hypoxia\u002Fischemia at the time of study\n* Infants with diaper rash or excoriated buttocks\n* Parents who are not fluent in English","25 Weeks","33 Weeks",{"count":82,"type":21},400,"OBSERVATIONAL","To address the current limitations related to infant pain assessment in the NICU, our international team of knowledge users and health\u002Fnatural science\u002Fengineering\u002Fsocial science researchers have come together to build a machine learning algorithm that will learn how to discriminate invasive and non-invasive distress. Furthermore, to improve the use of current pain management practices, our team seeks to better understand the developmental mechanisms underlying skin-to-skin contact over time and factors that may influence its efficacy in mitigating pain responses in preterm infants. This is an ongoing naturalistic observational study.",[31],[87,88,89,90,91,28],"NICU (Neonatal Intensive Care Unit)","Artificial Intelligence","Pain Assessment","Skin-to-Skin Contact","Parent Stress","2026-07-09",{"date":36,"type":37},{"date":95,"type":37},"2020-11-01",{"date":97,"type":21},"2031-03",{"name":99,"class":44},"York University",2,{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":53,"sex":17,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":100},"100053656","ketamine-versus-dexmedetomidine-as-an-adjuvant-in-scalp-block-in-supratentorial-brain-tumor-excision-surgeries-100053656","NCT07698665","Ketamine Versus Dexmedetomidine as an Adjuvant in Scalp Block in Supratentorial Brain Tumor Excision Surgeries","Efficacy of Ketamine Versus Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block in Adults Undergoing Supratentorial Brain Tumor Excision Surgeries for Hemodynamics and Pain Control, Double-blinded Randomized Study","Inclusion Criteria:\n\n* Age from 20 to 60 years, both sexes, American Society of Anesthesiologists (ASA) physical status II-III, Supratentorial tumor excision, Supine Position.\n\nand operation time: less than 6 hours.\n\nExclusion Criteria:\n\n* Patient refusal, disturbed consciousness level (Glasgow Coma Scale \\[GCS\\] \\\u003C 15). Patients who required reintubation during the study period, those not extubated. immediately after surgery, or those who awoke with neurological deficits impairing. pain assessments were excluded from the final analysis, history of psychotic disorders or previous surgeries, Poor cognitive function.\n\nPostictal state or uncontrolled\u002Frecurrent seizures, known allergy to dexmedetomidine or ketamine, difficult intubation (Mallampati score \\> III) or multiple intubation attempts, operation duration \\> 6 hours, renal dysfunction (creatinine \\> 1.2 mg\u002FdL, BUN \\> 20 mg\u002FdL), heart block and patients with chronic headache disorders or those receiving chronic analgesic therapy (for \\>3 months) were excluded.","20 Years","60 Years",{"count":111,"type":21},90,[24],"Supratentorial brain tumor surgeries are associated with significant nociceptive stimulation and postoperative pain, which may adversely affect patient outcomes. Scalp block has emerged as an effective regional anesthetic technique to improve analgesia and reduce opioid consumption.\n\nObjective: To compare efficacy of ketamine versus dexmedetomidine as adjuvants to bupivacaine in scalp blocks for supratentorial brain tumor surgeries, focusing on analgesia, opioid consumption, and hemodynamic stability.\n\nMethods:\n\nThis randomized double-blinded controlled trial included 80 patients undergoing supratentorial tumor excision, allocated equally into two groups: Group K received bupivacaine with ketamine (2 mg\u002Fkg), and Group D received bupivacaine with dexmedetomidine (1 µg\u002Fkg). Intraoperative hemodynamics, fentanyl consumption, postoperative pain scores (NRS), analgesic requirements, and complications were assessed.",[115,116,31],"Regional Anesthesia Morbidity","Supratentorial Brain Tumor",[118,119,120],"Scalp block","Dexemetomedine","Supratentorial","2026-07-07",{"date":36,"type":37},{"date":124,"type":37},"2026-01-01",{"date":126,"type":21},"2026-07-30",{"name":128,"class":44},"Cairo University",{"id":130,"slug":4,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":57,"conditions":133,"keywords":134,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":139,"leadSponsor":140,"locationsCount":45},"100635192",{"count":7,"type":21},[24],[31],[60,61,62],"2026-07-01",{"date":137,"type":37},"2026-07-02",{"date":121,"type":21},{"date":68,"type":21},{"name":70,"class":71},{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":17,"minAge":148,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":45},"100610288","phase-3-a-study-of-combogesic-iv-intravenous-in-pediatric-patients-with-acute-pain-100610288","NCT07225634","A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain","An Open Label, Pharmacokinetic and Safety Study of Combogesic® IV in Pediatric Patients With Acute Pain","Inclusion Criteria:\n\n1. Is male or female aged between 2 and \\\u003C17 years.\n2. Have a clinical indication of acute pain\\* requiring hospitalization and multiple doses of parenterally administered nonopioid analgesic medication for at least 0.5 - 5 days.\n3. Is either able to provide written informed consent or consent is provided from parents\u002Flegal guardians and assent provided from participants (where appropriate).\n4. Is willing and able to remain at the study site for at least 12 hours and to attend a follow-up visit at 7 ± 2 days after the last dose of study drug.\n5. Have negative HIV and hepatitis B \\& C test results.\n\n   * Acute pain indications may include but are not limited to post-operative pain associated with musculoskeletal or soft tissue surgery, fractures or injury, or medical procedures.\n\nExclusion Criteria:\n\n1. Has a known history of allergic reaction or clinically significant intolerance to acetaminophen, aspirin, opioids, or any nonsteroidal anti-inflammatory drugs (NSAIDs, including ibuprofen); history of NSAID-induced bronchospasm (subjects with the triad of asthma, nasal polyps, and chronic rhinitis are at greater risk for bronchospasm and should be considered carefully); or hypersensitivity, allergy, or significant reaction to sulfa (including sulfonamide) medicines, ingredients of the study drug, or any other drugs used in the study including anesthetics and antibiotics that may be required.\n2. Has experienced any surgical complications or other issues that, in the opinion of the Investigator, could compromise the safety of the subject if he or she participates in the study or could confound the results of the study.\n3. Has any clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, or renal disease or any other condition that, in the opinion of the Investigator, could compromise the subject's welfare, ability to communicate with the study staff, or otherwise contraindicate study participation.\n4. Has a history or current diagnosis of a significant psychiatric disorder that, in the opinion of the Investigator, would affect the subject's ability to comply with the study requirements.\n5. Has a history of a clinically significant (Investigator opinion) gastrointestinal (GI) event within 6 months before screening or has any history of peptic or gastric ulcers or GI bleeding.\n6. Has a surgical or medical condition of the GI or renal system that might significantly alter the absorption, distribution, or excretion of any drug substance.\n7. Is considered by the Investigator, for any reason to be an unsuitable candidate to receive the study drug.\n8. Is receiving systemic chemotherapy, has an active malignancy of any type, or has been diagnosed with cancer within 5 years before Screening (excluding treated squamous or basal cell carcinoma of the skin).\n9. Is currently receiving anticoagulants (e.g. heparin or warfarin).\n10. Has received a course of systemic corticosteroids (either oral or parenteral) within 3 months before screening (inhaled nasal steroids and regional\u002Flimited area application of topical corticosteroids (Investigator discretion) are allowed).\n11. Has a history of chronic use (defined as daily use for \\> 2 weeks) of NSAIDs, opiates, or glucocorticoids (except inhaled nasal steroids and regional\u002Flimited topical corticosteroids), for any condition within 6 months before study drug administration. Aspirin at a daily dose of ≤ 325 mg is allowed for cardiovascular prophylaxis if the subject has been on a stable dose regimen for ≥ 30 days before screening and has not experienced any relevant medical problem.\n12. Has a significant renal or hepatic disease, as indicated by clinical laboratory assessment (results ≥ 3 times the upper limit of normal \\[ULN\\] for any liver function test, including aspartate aminotransferase \\[AST\\], alanine aminotransferase \\[ALT\\], or creatinine ≥ 1.5 times the ULN).\n13. Has any clinically significant laboratory finding at screening that, in the opinion of the Investigator, contraindicates study participation.\n14. Participated in another clinical study within 30 days before Screening.\n15. Pregnant or lactating females\n16. Sexually active females of childbearing potential not using adequate contraception and sexually active males not using adequate contraception","2 Years","16 Years",{"count":151,"type":21},60,[153],"PHASE3","Combogesic® IV is an intravenous medicine (given by vein) containing a combination of two pain relief (analgesic) medicines called ibuprofen and acetaminophen. The goal of this clinical trial is to study the way that the body processes and clears the intravenous infusion of Combogesic® IV and that it is safe to be used in children and adolescents between the ages of 2 and \\\u003C17 years.\n\nWhat will the study involve for participants?\n\n* Combogesic® IV will be administered every 6 hours as necessary with a maximum of 4 doses within a 24-hour period as an intravenous infusion for about 15 minutes.\n* Participants will receive Combogesic® IV for a minimum of 12 hours (2 doses) up to a maximum of 5 days (20 doses). Dosing will be dependent on body weight.\n* If pain is not sufficiently controlled by Combogesic® IV, opioids may be used as supplementary pain relief at the discretion of the study doctor.\n* Have their blood samples collected before dosing and at specific times after dosing. The amount of study drug in the blood will be measured, and safety assessments (including blood and urine samples) will be done.\n* Rate the study drug at the end of the treatment.\n\nIt is expected that Combogesic® IV will be well tolerated in children and adolescents and that the pharmacokinetics findings will be similar as compared with adults.",[31],"2026-06-29",{"date":135,"type":37},{"date":159,"type":21},"2026-09",{"date":161,"type":21},"2027-04",{"name":163,"class":164},"AFT Pharmaceuticals, Ltd.","INDUSTRY",{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":176,"conditions":177,"keywords":178,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":45},"100430102","phase-2-twin-block-pain-medications-and-third-molar-extractions-100430102","NCT04880707","Twin Block, Pain Medications and Third Molar Extractions","Myogenous Face Pain Following Third Molar Extractions Under Intravenous Sedation","Inclusion Criteria:\n\n* All patients requiring extraction\u002Fs of at least 1 lower wisdom (third) molar that is partially\u002Ffully 'impacted', under intravenous sedation, are eligible to participate in this study so long as they\n\n  1. are older than 18 years of age,\n  2. are healthy,\n  3. have no cognitive\u002Fintellectual disability,\n  4. have no past\u002Frecent pain or reduced range of motion in their jaw joint\u002F muscle complex, no trauma or surgery in their jaw region.\n  5. have an electronic device such as a smart phone or a tablet\u002F computer with internet connection.\n  6. are willing to participate in the study and not be excluded by the following criteria below.\n\nExclusion Criteria:\n\n* Any patients, even if satisfying the criteria above, may not take part if they have any of the following:\n\n  1. Compromised ability to guard their self-interest, for e.g., prisoners, children, pregnant women, patients with intellectual\u002Fcognitive disability are not enrolled in the study.\n  2. Those patients who present with infection\u002Finflammation involving the third molars slated for extractions, on the day of their procedure, may not take part in the study.\n  3. In addition, those who have had opioid pain medication\u002Fs in the past to address short-term or long-standing pain, or those who are on long term prescription of anti-inflammatory pain medication, are unable to participate.\n  4. Those with long standing pain of the jaw joint or muscles.\n  5. Finally, those patients who are allergic to\u002Funable to tolerate either the dental local anesthetic or its components, opioids, acetaminophen ('Tylenol') or ibuprofen ('Motrin' or 'Advil') also may not take part in the study.",{"count":173,"type":21},48,[175],"PHASE2","Each year, over 3.5 million, mostly, healthy young adults, have their third molar teeth ('wisdom teeth') removed under sedation and are often given opioid prescriptions for managing their pain. Wisdom molar removal is one of the most common reasons for opioid prescriptions to be given to adolescents. There is a national thrust to reduce both the dose and the duration of such opioid prescriptions because even short-term opioid exposures increase risk for narcotic addiction and misuse. Non-opioid options to manage pain will still allow for sufficient pain control without risking addiction, and hence, a fundamental component of our response to combat the current national opioid crisis.\n\nThe investigators are going to study a promising option- the Twin Block dental anesthetic injection. The Twin block involves injecting the standard dental numbing medication in a way that 'numbs' the 'jaw-clencher' muscles on the side of the face. The investigators found that the Twin block relieved jaw pain stemming from these muscles, in a quick and sustained manner, even in patients whose pain following wisdom tooth removal primarily came from 'taut' and tender jaw-clencher muscles. However, what is not known is- how often do patients who have their wisdom teeth removed under sedation, end up in significant pain from taut and tender jaw-clencher muscles? Will using the twin block effectively reduce pain in such patients? In this pilot study, the investigators will examine wisdom molar extraction patients one day after their procedure. Those with significant pain (pain rated ≥ 5 on a 0-10 scale) in their jaw-clencher muscles, will get either the Twin block injection or a placebo. The investigators will track both 1) pain before and after the injection, and 2) pain medication usage over a 7-day period to see if both pain and opioid dosage come down with the Twin block. This study can support a simple, safe and inexpensive means to reduce pain after a common procedure.",[31],[179,180,181],"Twin block","Prescription opioids","Acute post-extraction pain","2026-06-17",{"date":184,"type":37},"2026-06-22",{"date":186,"type":37},"2024-03-11",{"date":188,"type":21},"2026-12",{"name":190,"class":44},"Rutgers, The State University of New Jersey",{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":201,"conditions":202,"keywords":204,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":212,"leadSponsor":213,"locationsCount":4},"100598188","phase-2-rectus-sheath-trial-100598188","NCT07068243","REctus Sheath Trial","Transverse Versus Longitudinal Approaches for Rectus Sheath Block: a Randomized Controlled Trial in Healthy Volunteers","REST","Inclusion criteria:\n\n1. Ability to provide written informed consent\n2. Ability and willingness to comply with the study procedures and duration requirements\n3. ASA physical status 1 or 2\n4. Age ≥ 18 years\n5. Weight \\> 60kg\n\nExclusion criteria:\n\n1. BMI \\> 40kg.m-2\n2. Use of analgesics within 24 hours before the procedure\n3. History of abdominal trauma or surgery\n4. Abdominal deformities or abnormalities that may prevent proper block performance\n5. Abdominal tattoos in the supraumbilical area\n6. Systemic neuromuscular disease\n7. Contraindications to regional anesthesia (e.g., infection, allergy)\n8. Structures are unable to be visualized by ultrasound\n9. Pregnancy\n10. Other known health conditions that would affect the participant's ability to successfully complete the study",{"count":7,"type":21},[175],"Regional anesthesia techniques (or nerve blocks) are used to provide sensory blockade over the abdominal wall. The most established technique is thoracic epidural. This provides bilateral spread but is also associated with neuraxial complications, which has led to a decrease in clinical usage. The rectus sheath block (RSB) is an established regional anesthesia technique used to provide somatic analgesia to the midline anterior abdominal wall by depositing local anesthetic in the posterior rectus sheath, thereby targeting the terminal anterior branches of the lower thoracic intercostal nerves. The conventional approach involves placing the ultrasound (US) probe transversely across the rectus abdominis muscle and advancing the needle in-plane either lateral-to-medial or medial-to-lateral. While this technique achieves spread within the sheath, the cephalocaudal distribution of local anesthetic may be suboptimal, potentially limiting the extent of dermatomal coverage. A longitudinal probe orientation, with needle insertion from cephalad to caudad, may theoretically facilitate a more extensive cranio-caudal spread by aligning the injection axis with the anatomical fascial plane of the posterior rectus sheath. However, the relative efficacy of these two approaches has not been investigated in a controlled, comparative setting. Thus, this randomized, single-blinded trial aims to evaluate the dermatomal sensory distribution and ultrasound-assessed local anesthetic spread achieved by the transverse versus longitudinal in-plane approaches to ultrasound-guided RSB in healthy adult volunteers. To compare the dermatomal sensory block distribution, investigators will use dermatomal mapping with pinprick, and cold.",[31,203],"Postoperative Pain, Acute",[205,206,207,208],"Rectus Sheath Block","Abdominal Block","Fascial Plane Block","RSB","2026-06-16",{"date":182,"type":37},{"date":159,"type":21},{"date":161,"type":21},{"name":214,"class":44},"Duke University",{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":53,"sex":17,"minAge":222,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":22,"phases":226,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":4},"100643043","the-effect-of-rhythmc-skn-tappng-and-internal-vbraton-appled-proxmal-to-the-procedure-ste-on-pan-and-fear-percepton-durng-pedatrc-perpheral-venpuncture-100643043","NCT07650591","THE EFFECT OF 'RHYTHMİC SKİN TAPPİNG' AND INTERNAL VİBRATİON APPLİED PROXİMAL TO THE PROCEDURE SİTE ON PAİN AND FEAR PERCEPTİON DURİNG PEDİATRİC PERİPHERAL VENİPUNCTURE","THE EFFECT OF 'RHYTHMİC SKİN TAPPİNG' AND INTERNAL VİBRATİON APPLİED PROXİMAL TO THE PROCEDURE SİTE ON PAİN AND FEAR PERCEPTİON DURİNG PEDİATRİC PERİPHERAL VENİPUNCTURE: A RANDOMİZED CONTROLLED TRİAL","Inclusion Criteria:\n\n* Being between 6 and 12 years of age\n\nRequiring a peripheral venipuncture procedure\n\nHaving written informed consent from the parents\n\nHaving verbal assent from the child\n\nBeing able to speak and understand Turkish\n\nHaving a cognitive development level appropriate for age\n\nAbsence of any chronic pain condition\n\nExclusion Criteria:\n\n* Refusing to participate in the study or wishing to withdraw at any stage\n\nDevelopment of complications during the procedure\n\nHaving used analgesics within the last 24 hours\n\nHaving previously participated in the same study\n\nImpaired skin integrity at the procedure site\n\nHaving a neurological or psychiatric diagnosis","6 Years","12 Years",{"count":225,"type":21},126,[24],"What is this study about, in short?\n\nThis study looks at simple, no-cost ways to reduce the pain and fear that children aged 6-12 feel when they have blood drawn at the hospital. Two methods are being tested:\n\n* A nurse lightly and rhythmically tapping with their fingertips just above the spot where the needle will go (\"rhythmic skin tapping\").\n* The child making an \"mmmm\" humming sound while the blood is being drawn (\"internal vibration\" or \"humming\").\n\nThese methods need no medicine and no device, so they can be used easily in any hospital. The study aims to find out whether these two methods really reduce pain and fear, by comparing them with a group that receives no extra method.\n\nWhy is this study being done? Drawing blood is one of the most common painful procedures in children. Fear of needles is very common and can even lead a person to avoid health care later in life. So it matters to make the blood-draw experience easier for children.\n\nSome methods used to reduce pain have practical limits:\n\n* Numbing creams must be applied 30-60 minutes before the procedure; they are not practical in urgent situations and add cost.\n* Special devices that give cold and vibration can work, but they can be expensive, are not always available, and need care for hygiene.\n\nFor these reasons, there is a need for simple methods that cost nothing, need no device, and can be applied easily in any setting. This study tests exactly that.\n\nHow do the methods work? (Simple science) Both methods rest on an idea called the \"Gate Control Theory\": in our body, the sense of touch and vibration competes with the sense of pain on the way to the brain. Gentle touch or mild vibration can act like a \"gate\" that partly blocks the pain signal from reaching the brain.\n\n* Rhythmic skin tapping: Gentle, rhythmic tapping with the fingers may help \"close the gate,\" so the pain is felt less.\n* Internal vibration (humming): The \"mmmm\" sound creates a mild vibration in the body. It can also stimulate the calming part of the nervous system, which may lower the heart rate and stress. Taking an active part in the procedure also gives the child a sense of control.\n\nWho can take part in the study?\n\nCan take part:\n\n* Children aged 6-12 years\n* Children who will have a blood draw\n* Children whose parent has given written permission and who themselves agree verbally\n* Children who can understand and speak Turkish\n* Children whose cognitive development is appropriate for their age\n* Children who do not have an ongoing (chronic) pain condition\n\nCannot take part, or will be withdrawn:\n\n* Children who do not want to take part, or wish to withdraw at any stage\n* Children who develop a complication (an unexpected medical problem) during the procedure\n* Children who have used a painkiller within the last 24 hours\n* Children who have already taken part in this study before\n* Children whose skin is broken at the site where the needle will go\n* Children who have a neurological or psychiatric diagnosis\n\nWhat will happen if my child takes part?\n\nThe blood draw will happen anyway because it is medically needed. The study only adds the method used during the draw and a short measurement afterward. Step by step:\n\n* Your child is placed by computer, at random (like drawing lots), into one of three groups. No one can choose the group in advance; this is called \"randomization\" and it keeps the comparison fair.\n* The blood draw is done as usual. The only difference is the method used, depending on your child's group.\n* Right after the procedure, the child is shown two short picture scales: one for pain, with faces ranging from smiling to crying (0-10), and one for fear, also made of faces (0-4).\n* A short form collects details such as age, sex, and any previous blood-draw experience.\n* No extra needle, medicine, or laboratory test is done beyond the routine blood draw.\n\nThe three groups are:\n\nGroup What is done in this group?\n\n1. Rhythmic skin tapping Gentle, rhythmic tapping with the fingertips just above the needle site.\n2. Internal vibration (humming) The child is asked to make an \"mmmm\" humming sound during the blood draw.\n3. Control group The blood draw is done as usual, with no extra method. This group is the comparison point used to measure the effect of the other two methods.\n\nWhere and when will the study take place?\n\n* Place: Kepez State Hospital Blood Collection Outpatient Clinic (Antalya, Türkiye).\n* Data collection period: June 2026 - June 2027. The total study duration is about 12 months.\n* Planned number of participants: 126 children in total (42 in each group). This number was set in advance by a statistical calculation so the results would be reliable.\n\nTaking part is completely voluntary\n\n* Your child does not have to take part. Even if you agree, you may withdraw at any time without giving a reason.\n* Not taking part, or withdrawing, will not affect the health care your child receives in any way.\n* Your child may also say they do not want the method; the child's decision is",[229,31,230,231,232,233],"Procedural Pain","Needle-Related Pain and Distress","Fear","Anxiety","Phlebotomy","2026-06-12",{"date":209,"type":37},{"date":237,"type":21},"2026-07",{"date":239,"type":21},"2027-06",{"name":241,"class":44},"Akdeniz University",{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":22,"phases":251,"briefSummary":252,"conditions":253,"keywords":256,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":45},"100617670","ultrasound-guided-regional-blocks-for-postoperative-analgesia-after-laparoscopic-cholecystectomy-100617670","NCT07321639","Ultrasound-Guided Regional Blocks for Postoperative Analgesia After Laparoscopic Cholecystectomy","Comparison of the Effectiveness of Ultrasound-Guided Recto-Intercostal Fascial Plane Block and Transversus Abdominis Plane Block in Postoperative Analgesia Management of Patients Undergoing Laparoscopic Cholecystectomy","Inclusion Criteria:\n\n* ASA physical status I-II\n* Scheduled for elective laparoscopic cholecystectomy\n\nExclusion Criteria:\n\n* Known allergy to local anesthetics or opioid medications\n* Infection at the planned block site\n* History of alcohol or drug dependence\n* Use of anticoagulant therapy\n* Refusal to participate in the study","65 Years",{"count":111,"type":21},[24],"Ultrasound (US)-guided recto-intercostal fascial plane block (RIFPB) is a recently described abdominal wall block performed by injecting local anesthetic between the rectus abdominis muscle and the costal cartilage of the 7th rib. Due to the cranial attachment of the rectus muscle, this technique provides effective analgesia to the sternal, epigastric, and upper-mid abdominal regions, corresponding to the T6-T10\u002F11 dermatomal levels. RIFPB may be used as an adjunct technique for thoracic procedures or as a standalone block for abdominal surgery.\n\nUltrasound-guided transversus abdominis plane block (TAPB) is performed by injecting local anesthetic into the fascial plane between the internal oblique and transversus abdominis muscles. TAPB provides sensory blockade of the anterolateral abdominal wall at the T6-L1 dermatomal levels and is widely used for postoperative analgesia following abdominal surgeries, including laparoscopic cholecystectomy.\n\nThis study aims to compare the effectiveness of US-guided RIFPB and TAPB on postoperative pain control after laparoscopic cholecystectomy.",[254,31,28,255],"Laparoscopic Cholecystectomy","Plane Blocks",[257,258,259,260,261,262],"Laparoscopic cholecystectomy","Postoperative analgesia","Recto-intercostal fascial plane block","Transversus abdominis plane block","Regional anesthesia","Opioid consumption","2026-06-10",{"date":265,"type":37},"2026-06-11",{"date":267,"type":37},"2026-01-19",{"date":269,"type":21},"2027-07-15",{"name":271,"class":44},"Istanbul Medipol University Hospital",{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":249,"enrollmentInfo":279,"targetDuration":4,"studyType":22,"phases":281,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":290,"leadSponsor":292,"locationsCount":45},"100643831","phase-4-effect-of-liposomal-bupivacaine-on-rebound-pain-after-peripheral-nerve-block-in-orthopedic-surgery-100643831","NCT07606911","Effect of Liposomal Bupivacaine on Rebound Pain After Peripheral Nerve Block in Orthopedic Surgery.","Liposomal Bupivacaine Combined With Plain Bupivacaine for Peripheral Nerve Block to Reduce Rebound Pain After Orthopedic Extremity Surgery: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* 18-65 years old;\n* ASA Physical Status 1-3;\n* Scheduled for elective unilateral orthopedic surgery of the upper or lower extremity.\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding;\n* Bupivacaine sensitivity or known allergy;\n* Contraindication for nerve blocks;\n* Enrollment in another clinical trial that could confound pain evaluation;\n* Other conditions that preclude study participation.",{"count":280,"type":21},668,[282],"PHASE4","This study will prospectively compare the preventive effect of liposomal bupivacaine combined with plain bupivacaine versus plain bupivacaine alone on rebound pain after nerve block in patients undergoing orthopedic extremity surgery. The primary aim is to assess whether the combination reduces the incidence or severity of rebound pain (i.e., more effectively covers the postoperative inflammatory peak on days 2-3 and provides a smoother regression curve of sensory blockade). Secondary aims include evaluation of upper limb functional scores, occurrence of chronic pain, and health-related quality of life. All aims will be assessed over 72 hours or the duration of hospitalization if shorter.",[31,285],"Orthopaedic Surgery","2026-06-07",{"date":288,"type":37},"2026-06-09",{"date":135,"type":21},{"date":291,"type":21},"2027-12-01",{"name":293,"class":44},"Shanghai Jiao Tong University Affiliated Sixth People's Hospital",{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":22,"phases":304,"briefSummary":305,"conditions":306,"keywords":311,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":323,"lastUpdatePostDateStruct":324,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":45},"100643654","comparison-of-iv-analgesia-protocols-after-the-regional-blocks-effect-diminishes-in-thoracic-surgery-100643654","NCT07610408","Comparison of IV Analgesia Protocols After the Regional Block's Effect Diminishes in Thoracic Surgery","Comparison of the Effectiveness of Intravenous Analgesia Protocols Used After the Duration of Block Action for Postoperative Pain Control in Thoracic Surgery","Inclusion Criteria:\n\n1. \\- Patients aged 18 to 80 years.\n2. \\- ASA (American Society of Anesthesiologists) Physical Status Score of I-III.\n3. \\- Body Mass Index (BMI) between 18 and 35 kg\u002Fm².\n4. \\- Undergoing elective thoracic surgery via Video-Assisted Thoracoscopic Surgery (VATS).\n5. \\- Voluntary participation confirmed by signing the written Informed Consent Form.\n\nExclusion Criteria:\n\n1. \\- Age below 18 or above 80 years.\n2. \\- Advanced organ failure (e.g., severe hepatic or renal impairment).\n3. \\- ASA physical status \\> III.\n4. \\- History of chronic pain treatment or long-term opioid use.\n5. \\- BMI \\\u003C 18 kg\u002Fm² or \\> 35 kg\u002Fm².\n6. \\- Pregnancy or breastfeeding.\n7. \\- Limited cooperation due to dementia or uncontrolled psychiatric disorders.\n8. \\- Communication barriers (inability to communicate in the native language).\n9. \\- History of substance or drug abuse.\n10. \\- Known allergy or contraindication to the study drugs (Fentanyl, Tramadol, or Ibuprofen).\n11. \\- Contraindication to regional block placement (e.g., infection at the injection site).","80 Years",{"count":303,"type":21},135,[24],"The purpose of this study is to compare the effectiveness of three different intravenous (IV) patient-controlled analgesia (PCA) regimens-Fentanyl, Tramadol, and Ibuprofen-in managing postoperative pain and respiratory performance in patients undergoing Video-Assisted Thoracoscopic Surgery (VATS). While regional blocks like Erector Spinae Plane (ESP) block provide effective early analgesia, their effect typically diminishes after 8-12 hours, leading to potential 'rebound pain.' This study specifically investigates the period following the duration of the regional block's action. The primary goal is to evaluate which IV PCA protocol better controls pain (Visual Analog Scale scores) and supports better respiratory performance (measured by incentive spirometry) during the first 72 hours post-surgery",[307,308,309,310,31],"Postoperative Pain After Thoracic Surgery","Postoperative Pain","Thoracic Surgery, Video Assisted","Patient Controlled Analgesia",[312,313,314,315,316,317,318,319,320,321,322],"Video-Assisted Thoracoscopic Surgery","VATS","Erector Spinae Plane Block","ESP","Patient-Controlled Analgesia","PCA","IV analgesia","Incentive spirometry","Opioid-sparing","Postoperative pain after thoracic surgery","Rebound Pain","2026-06-06",{"date":288,"type":37},{"date":326,"type":37},"2026-06-02",{"date":328,"type":21},"2026-10-15",{"name":330,"class":331},"Ankara Etlik City Hospital","OTHER_GOV",{"id":333,"slug":334,"hasResults":12,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":249,"enrollmentInfo":339,"targetDuration":4,"studyType":22,"phases":341,"briefSummary":342,"conditions":343,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":351,"locationsCount":45},"100640032","the-5050-nitrous-oxide-vs-2-lidocaine-challenge-100640032","NCT07618676","The 50:50 Nitrous Oxide vs 2% Lidocaine Challenge","The 50:50 Nitrous Oxide Challenge: A Prospective Randomised Trial - Needle, Meet Your Match","Inclusion Criteria:\n\n* Subjects who have not previously received Nitrous Oxide.\n* Subjects of both sexes, aged between 18 and 65 inclusive.\n* Subjects who have signed informed consent with full disclosure; no study-related procedure may begin until the subject signs the consent form.\n\nExclusion Criteria:\n\n* Infection at the planned puncture site.\n* Pregnancy.\n* Intracranial hypertension.\n* Vitamin B12 deficiency.\n* Hemodynamic instability.\n* BMI over 35.\n* Glasgow Coma Scale (GCS) score less than 15.\n* Presence of chronic pain.\n* Neurological disorders.\n* Hematologic disorders.\n* More than two attempts at venous puncture (Subject Withdrawal Criterion).\n* Subject experienced an adverse event requiring early discontinuation (Subject Withdrawal Criterion).\n* Withdrawal of consent by the subject (Subject Withdrawal Criterion)",{"count":340,"type":21},62,[24],"The main goal of the project is to assess pain levels and patient comfort during the administration of a 50:50 Nitrous Oxide\u002FOxygen gas mixture, in comparison to the same parameters under the standard method used at our institution, which includes injecting a local anaesthetic at the site of planned puncture for central venous catheterisation.",[31,232,344],"Central Venous Catheter","2026-05-25",{"date":347,"type":37},"2026-06-01",{"date":349,"type":37},"2025-06-06",{"date":135,"type":21},{"name":352,"class":44},"Institute for Oncology and Radiology of Serbia",{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":362,"conditions":363,"keywords":366,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":45},"100551965","understanding-the-acute-pain-phenotype-in-patients-undergoing-surgery-100551965","NCT06466941","Understanding the Acute Pain Phenotype in Patients Undergoing Surgery","Impact of Patient Phenotypic Features on the Experience and Effectiveness of Regional Anesthesia and Postoperative Pain","Inclusion Criteria:\n\n* Age ≥ 18\n* English speaking\n* Surgical or procedural patient who will be admitted postoperatively\n* Willingness to answer psychosocial survey and\u002For audio recorded semi-structured interview\n\nExclusion Criteria:\n\n-Cognitive dysfunction that precludes communication",{"count":361,"type":21},1000,"The goal of this observational study is to learn about how regional anesthesia (numbing medication) affects pain in patients with different psychosocial phenotypes such as different levels of concern about pain, sleep issues, and anxiety, who are having surgery.\n\nThe main questions are:\n\n1. Do psychosocial factors such as concerns about pain, sleep, anxiety affect the effectiveness of regional anesthesia?\n2. Do psychosocial factors and regional anesthesia affect the amount of opioids used after surgery?\n3. Do psychosocial factors and regional anesthesia affect development of chronic postsurgical pain?",[31,364,365],"Chronic Post Operative Pain","Opioid Use",[367,368,369,370],"regional anesthesia","peripheral nerve blocks","psychosocial phenotype","pain catastrophizing","2026-05-20",{"date":373,"type":37},"2026-05-22",{"date":375,"type":37},"2024-07-03",{"date":377,"type":21},"2028-12-31",{"name":379,"class":44},"Brigham and Women's Hospital",{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":387,"enrollmentInfo":388,"targetDuration":4,"studyType":22,"phases":390,"briefSummary":392,"conditions":393,"keywords":395,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":404,"completionDateStruct":405,"leadSponsor":407,"locationsCount":4},"100637582","early-phase-1-pain-induced-by-m-cresol-as-preservative-100637582","NCT07600814","Pain Induced by m-Cresol as Preservative","Pain Induced by m-Cresol as Preservative - A Randomised Controlled Crossover-Trial in Healthy Volunteers","Inclusion criteria\n\n* Age between 18 and 70 years\n* Full legal capacity Exclusion criteria\n* Participant of another study, ongoing or within the last four weeks\n* Current medication intake (except hormonal contraception) or drug abuse\n* Female subjects: Positive pregnancy test or breastfeeding\n* Body temperature above 38°C, verified by infrared thermometer\n* Known allergic diseases, in particular asthmatic disorders and skin diseases\n* Sensory deficit, skin disease or hematoma of unknown origin in the examination of the test site","70 Years",{"count":389,"type":21},18,[391],"EARLY_PHASE1","Preservatives such as m-Cresol are essential components in many subcutaneously injected medications, including insulin or human growth hormone, to prevent bacterial growth. However, clinical reports have suggested that these preservatives may cause local discomfort or pain at the injection site, which can negatively impact treatment adherence. While m-Cresol is widely used, its direct contribution to injection-site pain has not yet been investigated in a prospective clinical trial.\n\nThis study aims to investigate whether subcutaneous injection of m-Cresol at concentrations commonly used in clinical practice (0.1% and 0.25%) cause significantly more pain than a preservative-free control solution. In a randomized, double-blind crossover design, healthy volunteers will receive three separate injections in a belly fold. Participants will rate their pain every 5 seconds until it subsides. The findings will help determine if m-Cresol is a primary source of injection-site pain and could lead to the development of more comfortable drug formulations.",[27,31,394],"Healthy Volunteer Study",[396,397,398,399,400,401],"m-Cresol","Preservative","Subcutaneous Injection","Human Pain Models","Experimental Pain Models","Nociception","2026-05-15",{"date":373,"type":37},{"date":345,"type":21},{"date":406,"type":21},"2026-06-08",{"name":408,"class":44},"Medical University of Vienna",{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":417,"enrollmentInfo":418,"targetDuration":4,"studyType":22,"phases":420,"briefSummary":421,"conditions":422,"keywords":427,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":442,"locationsCount":4},"100636768","efficacy-and-safety-of-high-concentration-35-kda-hyaluronan-gel-for-herpes-zoster-associated-pain-100636768","NCT07569978","Efficacy and Safety of High-Concentration 35 kDa Hyaluronan Gel for Herpes Zoster-Associated Pain","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate the Efficacy and Safety of Topical 10% High-Concentration 35 kDa Hyaluronan (HA35) Gel in Subjects With Herpes Zoster-Associated Pain","HA35-HZ","Inclusion Criteria:\n\n* Age 18-85 years, male or female\n* Clinically diagnosed with herpes zoster-associated pain (acute ZAP or PHN)\n* Baseline pain NRS score ≥5\n* Ability to understand and complete NRS assessments\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Acute bacterial skin infection at the application site\n* Use of topical analgesics or antiviral therapy within 24 hours\n* Systemic analgesic use within 6 hours\n* Known hypersensitivity to hyaluronan or gel components\n* Pregnant or lactating women\n* Severe systemic disease or malignant tumor","85 Years",{"count":419,"type":21},30,[24],"This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel in subjects with herpes zoster-associated pain (ZAP). Eligible participants will receive a single topical application of the study gel. The primary objective is to assess rapid pain reduction within 2 minutes and 24hours after application. Secondary objectives include evaluation of analgesic duration, local tolerability, erythema improvement, and overall safety throughout the observation period. This is a minimal-risk, non-pharmacological supportive care intervention.",[423,424,425,426,31],"Herpes Zoster","Zoster-Associated Pain","Postherpetic Neuralgia","Neuropathic Pain",[428,429,430,431,423,432,425,426,433,434,435],"Hyaluronan","35 kDa Hyaluronan","HA35","Topical Gel","Zoster Pain","Analgesia","Non-pharmacological Intervention","Pilot Clinical Study","2026-05-05",{"date":438,"type":37},"2026-05-08",{"date":440,"type":21},"2026-05-01",{"date":34,"type":21},{"name":443,"class":164},"Nakhia Impex LLC",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":22,"phases":453,"briefSummary":454,"conditions":455,"keywords":457,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":464,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":468,"locationsCount":4},"100636486","phase-4-study-of-ql-analgesic-response-and-extent-100636486","NCT07566312","Study of QL Analgesic Response and Extent","Anterior Versus Posterior Versus Lateral Quadratus Lumborum Block: a Randomized Control Trial in Healthy Volunteers","SQUARE","Inclusion Criteria:\n\n* Ability to provide written informed consent\n* Ability and willingness to comply with the study procedures and duration requirements\n* ASA physical status 1 or 2\n* Age ≥ 18 years\n* Weight \\> 70kg\n\nExclusion Criteria:\n\n* BMI \\> 35kg.m2\n* Use of analgesics within 24 hours before the procedure\n* History of thoracic trauma or surgery\n* Abdominal deformities or abnormalities that may prevent proper block performance\n* Abdominal tattoos in the area of block performance\n* Systemic neuromuscular disease\n* Contraindications to regional anesthesia (e.g., infection, allergy, challenging sonoanatomy)\n* Structures are unable to be visualized by ultrasound\n* Pregnancy\n* Other known health conditions that would affect the participant's ability to successfully complete the study",{"count":7,"type":21},[282],"A total of 14-18 healthy volunteers will be included. There will be three different procedure days, separated by at least one week. On each visit, the subjects will receive a QL block, according to the randomization process. Each volunteer will undergo pre-procedure screening on the first visit. The blocks will be performed on the same side, by the same anesthesiologist, with at least one week between each block. An anterior QL block will be administered on one day, a posterior QL block on another, and a lateral QL block on the third. The order will be randomized, and both the subject and the research team member assessing the block will be blinded. To compare the dermatomal sensory block distribution, the investigators will use detailed mapping with pinprick, cold, and heat stimuli. A handheld dynamometric assessment of lower extremity strength. The testing will be performed 60 to 90 minutes after performance of the blocks.",[31,308,456],"Regional Anesthesia Block",[458,459,460,461,462,261,463],"Quadratus lumborum block","QL block","QL","Quadratus lumborum","Fascial plane block","Abdominal blocks",{"date":436,"type":37},{"date":466,"type":21},"2026-05",{"date":188,"type":21},{"name":214,"class":44},{"id":470,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":22,"phases":472,"briefSummary":25,"conditions":473,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":476,"completionDateStruct":477,"leadSponsor":478,"locationsCount":45},"100636186",{"count":20,"type":21},[24],[27,28,29,30,31,32],"2026-04-27",{"date":440,"type":37},{"date":440,"type":21},{"date":41,"type":21},{"name":43,"class":44},{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":486,"enrollmentInfo":487,"targetDuration":4,"studyType":22,"phases":489,"briefSummary":490,"conditions":491,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":495,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":499,"locationsCount":45},"100632294","phase-2-a-study-of-ly4515100-in-participants-with-pain-following-third-molar-removal-100632294","NCT07511816","A Study of LY4515100 in Participants With Pain Following Third Molar Removal","A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Single Oral Dose of LY4515100, in Participants Experiencing Moderate-to-Severe Acute Pain Following Surgical Removal of Impacted Third Molars","Inclusion Criteria:\n\n* Participant has a body mass index (BMI) between 18.5 and 35.0 kilograms per meter squared (kg\u002Fm²) inclusive.\n* Participant requires extraction of 2 or more third molars, including 2 mandibular molars with partial or full bony impaction, confirmed by panoramic X-ray.\n\nExclusion Criteria:\n\n* Prior dental surgery within 60 days before screening or history of other surgical procedures that could confound surgery or postoperative procedures.\n* Diagnosis of chronic pain conditions that could confound postsurgical pain reporting in the opinion of the investigator.\n* Positive urine drug screen or alcohol test during screening or on the day of surgery.\n* Evidence or history of any other clinically significant hematological, renal, hepatic, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, or neurologic diseases, in the opinion of the investigator, within the last 5 years.\n* History of malignancy of any organ system treated or untreated, within 5 years prior to consent. The only exceptions are previous in situ carcinoma of the cervix, localized basal cell carcinoma of the skin, or localized squamous carcinoma of the skin if the participant has been treated and is considered cured.","40 Years",{"count":488,"type":21},212,[175],"The purpose of this study is to evaluate the safety and efficacy of LY4515100 and see how a single oral dose compares with placebo in acute postsurgical pain after removing impacted third molars. For each participant, the study may last approximately 6 weeks and will include a stay in a Clinical Research Unit (CRU) after third molar removal.",[31,492,493,494],"Molar","Molar, Third","Surgery, Oral",{"date":440,"type":37},{"date":497,"type":37},"2026-04-01",{"date":188,"type":21},{"name":500,"class":164},"Eli Lilly and Company",{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":507,"eligibilityCriteria":508,"healthyVolunteers":53,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":22,"phases":511,"briefSummary":512,"conditions":513,"keywords":514,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":524,"locationsCount":45},"100635510","the-effect-of-shotblocker-on-pain-anxiety-and-satisfaction-during-peripheral-intravenous-catheterization-100635510","NCT07553624","The Effect of ShotBlocker on Pain, Anxiety, and Satisfaction During Peripheral Intravenous Catheterization","The Effect of Shotblocker on Pain, Anxiety, and Satisfaction During Peripheral Intravenous Catheterization: A Randomized Controlled Trial","SB-PIVC","Inclusion Criteria:\n\nIndividuals aged 18 years and older Patients requiring peripheral intravenous catheterization Patients who are conscious and able to communicate Patients who agree to participate in the study and provide informed consent\n\nExclusion Criteria:\n\nPatients with cognitive impairment or inability to communicate Patients with a history of chronic pain or current use of analgesics Patients with dermatological conditions or wounds at the catheterization site Patients who previously experienced peripheral intravenous catheterization within the last 24 hours Patients who refuse to participate in the study",{"count":510,"type":21},100,[24],"This randomized controlled trial aims to evaluate the effect of the ShotBlocker device on pain, anxiety, and patient satisfaction during peripheral intravenous catheterization (PIVC). Peripheral intravenous catheterization is a commonly performed procedure in clinical settings and is often associated with pain and anxiety, which may negatively affect patient experience.\n\nThe ShotBlocker is a simple, non-pharmacological device designed to reduce pain by applying pressure and sensory stimulation at the injection site. Participants will be randomly assigned to either the intervention group, where the ShotBlocker will be used during the procedure, or the control group, where routine care will be provided.Pain will be assessed using the Visual Analog Scale (VAS). Anxiety and patient satisfaction will be evaluated using a visual analog-based scale supported , combining features of the Visual Analog Scale and the Wong-Baker Faces Scale, with scores ranging from 0 to 10. The findings of this study are expected to contribute to evidence-based nursing practices by providing an effective, low-cost, and non-invasive method for reducing procedural discomfort and improving patient experience during PIVC.",[31,232],[515,516,27,232,517],"Peripheral Intravenous Catheterization","ShotBlocker","Patient Satisfaction","2026-04-23",{"date":520,"type":37},"2026-04-28",{"date":522,"type":21},"2026-04-18",{"date":466,"type":21},{"name":525,"class":44},"Kirsehir Ahi Evran Universitesi",{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":249,"enrollmentInfo":533,"targetDuration":4,"studyType":22,"phases":534,"briefSummary":535,"conditions":536,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":541,"leadSponsor":543,"locationsCount":45},"100615305","comparing-the-postoperative-analgesic-efficacy-of-anterior-iliac-block-and-ilioinguinal-iliohypogastric-block-in-inguinal-hernia-surgery-100615305","NCT07290881","Comparing the Postoperative Analgesic Efficacy of Anterior Iliac Block and Ilioinguinal-iliohypogastric Block in Inguinal Hernia Surgery","A Prospective Randomized Study Comparing the Postoperative Analgesic Efficacy of Anterior Iliac Block and Ilioinguinal-iliohypogastric Block in Inguinal Hernia Surgery","Inclusion Criteria:\n\n* It includes patients aged 18-65 years\n* Classified as ASA I-II\n* Who are undergoing elective inguinal hernia surgery\n\nExclusion Criteria:\n\n* Patients who did not wish to participate voluntarily\n* Those with contraindications to the anterior iliac block or the Ilioinguinal\u002FIliohypogastric block,\n* Pregnant or breastfeeding women\n* Patients classified as ASA III-IV-V",{"count":151,"type":21},[24],"The primary aim of this study is to compare two postoperative analgesia techniques used in patients undergoing inguinal hernia surgery-(1) the anterior iliac block and (2) the ilioinguinal\u002Filiohypogastric block-in terms of postoperative analgesia duration and patient satisfaction.\n\nEffective postoperative analgesia in inguinal hernia surgery is crucial for improving patient comfort and reducing opioid consumption. Although ilioinguinal and iliohypogastric nerve blocks are commonly used for this purpose, their relatively limited dermatomal coverage may result in inadequate analgesia in some cases. The recently described Anterior Iliac Block has been proposed as an alternative to conventional techniques, offering potentially wider neural spread and more effective postoperative pain control. However, the efficacy and safety of this novel block have not yet been sufficiently evaluated in the literature.",[31],"2026-04-20",{"date":539,"type":37},"2026-04-21",{"date":537,"type":37},{"date":542,"type":21},"2026-09-01",{"name":544,"class":44},"Harran University",{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":53,"sex":552,"minAge":18,"maxAge":553,"enrollmentInfo":554,"targetDuration":4,"studyType":22,"phases":556,"briefSummary":557,"conditions":558,"keywords":570,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":45},"100632191","effects-of-breastfeeding-virtual-reality-and-stress-ball-on-pain-anxiety-cortisol-levels-and-comfort-during-episiotomy-repair-100632191","NCT07510477","Effects of Breastfeeding, Virtual Reality, and Stress Ball on Pain, Anxiety, Cortisol Levels, and Comfort During Episiotomy Repair","Effects of Breastfeeding, Virtual Reality, and Stress Ball on Pain, Anxiety, Cortisol Levels, and Comfort During Episiotomy Repair in Primiparous Women: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Pregnant women between 18 and 45 years of age.\n* Primiparous women (first-time mothers).\n* Gestational age between 37 and 42 weeks (term pregnancy).\n* Singleton pregnancy with a vertex presentation.\n* Spontaneous vaginal delivery requiring a mediolateral episiotomy.\n* Newborn birth weight between 2500 and 4500 grams.\n* Newborn Apgar scores of 7 or higher at the 1st and 5th minutes.\n* Ability to read, understand, and speak Turkish fluently.\n* Voluntary participation with signed informed consent.\n\nExclusion and Withdrawal Criteria:\n\n* Requesting to withdraw from the research at any stage.\n* Presence of any congenital anomalies in the newborn.\n* Presence of maternal visual or hearing impairments.\n* Occurrence of fetal mortality or morbidity.\n* Occurrence of anal sphincter injury or 3rd\u002F4th-degree lacerations in addition to the episiotomy.\n* Performance of the episiotomy repair in an operating room.\n* Use of assisted delivery methods (e.g., vacuum extraction).\n* Administration of sedative drugs or extra anesthetic agents (excluding routine local perineal infiltration).\n* Development of maternal complications (e.g., postpartum hemorrhage) preventing data collection.","FEMALE","45 Years",{"count":555,"type":21},120,[24],"The goal of this clinical trial is to learn about the effects of three different interventions-breastfeeding, using a stress ball, or wearing virtual reality (VR) goggles-on pain, anxiety, and stress during episiotomy repair (stitching) after childbirth. It also aims to examine how these methods affect a mother's comfort after the procedure.\n\nThe main questions it aims to answer are:\n\nDoes breastfeeding, using a stress ball, or using VR goggles lower the mother's pain and anxiety during the repair? Do these interventions reduce the mother's biological stress levels, measured by saliva cortisol tests? Do these methods lead to higher postpartum comfort levels for the mother in the first 24 hours after birth?\n\nResearcher will compare these three intervention groups to a \"control group\" (mothers receiving standard hospital care) to see which approach is most effective.\n\nParticipants will:\n\nBe randomly assigned to one of four groups: Breastfeeding, VR Goggles, Stress Ball, or Standard Care.\n\nUse their assigned intervention throughout the entire episiotomy repair process.\n\nProvide saliva samples before and after the procedure to measure stress hormones (cortisol).\n\nRate their pain and anxiety levels using clinical scales twice: once before the procedure begins and once immediately after it is finished.\n\nComplete a survey about their comfort levels between 6 and 24 hours after the delivery.",[559,560,561,562,232,563,564,565,566,567,31,568,569],"Episiotomy","Breastfeeding","Virtual Reality","Virtual Goggles","Cortisol","Postpartum Comfort","Postpartum Comfort Scale","Stress Physiological","PAIN, ANXIETY, AND COMFORT","Stress Ball","Midwifery",[560,561,568,571,572,573,574,559,575],"Midwifery Care","Primiparous Women","Randomized Controlled Trial","Salivary Cortisol","Episiotomy Repair","2026-03-30",{"date":578,"type":37},"2026-04-03",{"date":580,"type":21},"2026-04",{"date":582,"type":21},"2027-09",{"name":584,"class":44},"Aydin Adnan Menderes University",{"id":586,"slug":4,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":590,"targetDuration":4,"studyType":22,"phases":591,"briefSummary":592,"conditions":593,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":45},"100618710","NCT07335159","Does Patient Testimonial Improve the Pain Relief Derived From a Brief Intervention","Does Patient Testimonial Improve the Pain Relief Derived From a Brief Behavioral Intervention Delivered to Patients Experiencing Pain in a Clinic Waiting Room",{"count":82,"type":21},[24],"This project is a single-site, two-arm, randomized controlled trial investigating whether providing patients in an orthopedic clinic waiting room an audio-recorded mindfulness practice decreases their pain relative to an injury management control condition.",[27,31,32,28],"2026-03-27",{"date":576,"type":37},{"date":597,"type":37},"2026-01-05",{"date":599,"type":21},"2026-05-30",{"name":43,"class":44},{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":607,"eligibilityCriteria":608,"healthyVolunteers":12,"sex":552,"minAge":18,"maxAge":553,"enrollmentInfo":609,"targetDuration":4,"studyType":22,"phases":610,"briefSummary":611,"conditions":612,"keywords":614,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":627,"locationsCount":45},"100630218","virtual-reality-intervention-to-reduce-pain-in-women-undergoing-elective-oocyte-cryopreservation-100630218","NCT07484815","Virtual Reality Intervention to Reduce Pain in Women Undergoing Elective Oocyte Cryopreservation","The Effectiveness of Virtual Reality for Pain Reduction in Women Undergoing Elective Oocyte Cryopreservation: A Randomized Controlled Trial","OPU-VR","Inclusion Criteria:\n\n* Women undergoing elective oocyte retrieval for fertility preservation.\n* Age 18-45 years.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Use of pain relief, anti-anxiety, or antidepressant medications prior to the intervention.\n* Any condition for which VR use is not recommended, including:\n\n  * History of seizures\n  * Sensitivity to flashing light or motion\n  * Migraine headaches\n  * Predisposition to nausea or dizziness (e.g., vertigo)\n* Any injury to the eyes, face, or neck limiting use of the VR device, including blindness.",{"count":510,"type":21},[24],"This randomized controlled study evaluates whether exposure to relaxing virtual reality (VR) scenery prior to oocyte retrieval can reduce pain in women undergoing elective oocyte cryopreservation.\n\nMany women experience discomfort before and after oocyte retrieval. Virtual reality has been shown to reduce pain in various medical settings by providing distraction and relaxation.\n\nIn this study, participants are randomly assigned to receive either routine care alone or routine care combined with a VR-based relaxation intervention while waiting for the procedure.\n\nPain is assessed using validated questionnaires and standardized scales before and after oocyte retrieval.\n\nThe results of this study may help determine whether VR can serve as a simple, safe, and non-pharmacological method to improve patient comfort during elective egg freezing.",[613,31],"Procedure-Related Pain",[561,615,28,616,617,618,619,620],"Oocyte Retrieval","Fertility Preservation","Non-Pharmacological Intervention","Reproductive Medicine","Patient Comfort","Elective Oocyte Cryopreservation","2026-03-18",{"date":623,"type":37},"2026-03-20",{"date":625,"type":37},"2024-11-05",{"date":188,"type":21},{"name":628,"class":44},"Hadassah Medical Organization",{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":4,"eligibilityCriteria":635,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":301,"enrollmentInfo":636,"targetDuration":4,"studyType":22,"phases":638,"briefSummary":639,"conditions":640,"keywords":643,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":648,"lastUpdatePostDateStruct":649,"startDateStruct":651,"completionDateStruct":653,"leadSponsor":655,"locationsCount":45},"100629255","comparison-of-erector-spinae-plane-block-espb-with-the-combination-of-superficial-parasternal-intercostal-plane-block-spipb-and-serratus-anterior-plane-block-sapb-in-the-management-of-postoperative-sternotomy-pain-in-patients-undergoing-cardiac-surgery-via-sternotomy-100629255","NCT07472296","Comparison of Erector Spinae Plane Block (ESPB) With the Combination of Superficial Parasternal Intercostal Plane Block (SPIPB) and Serratus Anterior Plane Block (SAPB) in the Management of Postoperative Sternotomy Pain in Patients Undergoing Cardiac Surgery Via Sternotomy","Sternotomi İle Kardiyak Cerrahi Planlanan Hastalarda Postoperatif Sternotomi Ağrısının Yönetiminde Erektör Spina Plan Blok (ESPB) Ile Yüzeyel Parasternal İnterkostal Plan Bloğu (SPIPB) ve Serratus Anterior Plan Bloğu (SAPB) Kombinasyonunun Karşılaştırılması","Inclusion Criteria:\n\n* Patients aged between 18 and 80 years.\n* Patients classified as American Society of Anesthesiologists (ASA) physical status I, II, or III.\n* Patients scheduled for elective cardiac surgery via median sternotomy.\n* Patients who have provided written informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or suspected pregnancy.\n* Body Mass Index (BMI) \\> 35 kg\u002Fm².\n* Known allergy or hypersensitivity to local anesthetics (e.g., bupivacaine).\n* Suspected coagulopathy or bleeding disorders.\n* Infection at the site of the regional block injection.\n* Severe hepatic or renal failure.\n* Severe neurological or psychiatric disorders.\n* Emergency surgical procedures.\n* Re-operation cases (Redo-surgery)",{"count":637,"type":21},50,[24],"This study aims to compare the effectiveness of two regional anesthesia techniques in managing pain for participants undergoing cardiac surgery via sternotomy. The investigators will evaluate whether the Erector Spinae Plane Block (ESPB) or a combination of the Superficial Parasternal Intercostal Plane Block (SPIPB) and Serratus Anterior Plane Block (SAPB) provides better pain control and recovery outcomes.",[308,641,31,642,28],"Sternotomy Pain","Cardiac Surgery",[314,644,645,646,647],"Serratus Anterior Plane Block","Superficial Parasternal Intercostal Plane Block","Opioid Consumption","Multimodal Analgesia","2026-03-13",{"date":650,"type":37},"2026-03-16",{"date":652,"type":37},"2025-11-01",{"date":654,"type":21},"2026-11",{"name":656,"class":44},"Uludag University"]